source
- Alnylam cuts Amvuttra sales guidance as demand shifts, hurting stockAlnylam’s second-quarter earnings report Thursday did little to assuage investor concerns in what has already been a difficult year for the company. The drugmaker lowered its full-year sales projec…Endpoints · 8h ago↗ source
- Daiichi’s pipeline falls behind rivals as cash flow nears peak: analystsWith Enhertu and Datroway hitting their peak revenue and rivals flowing into the antibody-drug conjugate space, Jefferies cuts expectations for Daiichi Sankyo.BioSpace · 8h ago↗ source
- Relation promises 'transformationally different success rates' in expanded AI pact with GSKGSK is set to pay Relation Therapeutics up to $110 million to expand their existing partnership to use AI modeling for drug discovery. Under the Thursday deal, Relation will build a ...